A precise, high-throughput solution to analyze your samples at scale and speed.
CellCarta’s next-generation sequencing services provide a rapid turnaround time in results to support biomarker discovery, patient stratification, and therapeutic development.
The clinical applications of NGS are numerous, including whole genome sequencing, whole exome sequencing, mutation and copy number variation (CNV) analysis, fusion detection, drug resistance investigations, minimal residual disease (MRD) detection, tumor profiling, and pharmacogenetics.
Our NGS solutions can be scaled to meet your studies at every stage.
We offer a selection of NGS panels validated for clinical use to support patient selection, including:
Our laboratories are CAP/CLIA and GLP accredited to meet the highest standards of clinical trial requirements, and to meet the needs your NGS and RNAseq studies.
CellCarta can accommodate a wide portfolio of off-the-shelf (OTS) NGS assays for rapid implementation. This includes:
Custom panel development for NGS is offered. Contact us to learn more.
CellCarta’s NGS services are powered by a suite of high-performance sequencing platforms, including:
Our platforms can support sequencing projects of any scale and will accommodate all biological matrices.
Our cross-validated instrumentation and processes ensure seamless global support across regions without compromising consistency or quality.
Our team provides detailed analysis and interpretation of NGS data to uncover key biological insights.
Our Illumina workflows are analyzed using Illumina Connected Analytics (ICA), enabling pipeline customization and scalability.
We can enhance the analytical capabilities of standard pipelines to provide custom computational pipeline development for advanced applications. We can also integrate insights from across our other services, ensuring thorough genomic analysis.
We offer a selection of NGS panels validated for clinical use to support patient selection, including:
Our laboratories are CAP/CLIA and GLP accredited to meet the highest standards of clinical trial requirements, and to meet the needs your NGS and RNAseq studies.
CellCarta can accommodate a wide portfolio of off-the-shelf (OTS) NGS assays for rapid implementation. This includes:
Custom panel development for NGS is offered. Contact us to learn more.
CellCarta’s NGS services are powered by a suite of high-performance sequencing platforms, including:
Our platforms can support sequencing projects of any scale and will accommodate all biological matrices.
Our cross-validated instrumentation and processes ensure seamless global support across regions without compromising consistency or quality.
Our team provides detailed analysis and interpretation of NGS data to uncover key biological insights.
Our Illumina workflows are analyzed using Illumina Connected Analytics (ICA), enabling pipeline customization and scalability.
We can enhance the analytical capabilities of standard pipelines to provide custom computational pipeline development for advanced applications. We can also integrate insights from across our other services, ensuring thorough genomic analysis.
CellCarta has partnered with Pillar Biosciences to broaden access to quick, operationally streamlined NGS tumor profiling. Combining Pillar’s portfolio of oncoReveal kitting panels with our global network and expertise provides increased support for clinical trials and CDx programs.
The TSO500 ctDNA v2 assay enables genomic profiling from plasma — a non-invasive, repeatable, and rapid method to track tumor evolution. CellCarta validated the TSO500 ctDNA v2 analytical performance, demonstrating its ability to deliver reproducible, high-resolution data suited for clinical studies.
Incorporate customizable NGS solutions to accelerate your genomics research.
Scalable Solutions
High-Performance Sequencing
Global Execution
Clinical Implementation
Cross-Validated Protocols
Nucleic acid quantification with superior accuracy, precision, and sensitivity.
Comprehensive analysis through various platforms, including RareCyte® and TSO500.
Comprehensive analysis of all genomic data tailored to your specific project needs.
NGS has several clinical applications, including whole genome, whole exome, RNA, and cfDNA sequencing, mutation and CNV analysis, fusion detection, drug resistance and interaction studies, tumor profiling, TCR/BCR sequencing, pharmacogenetics, MRD detection, and spatial transcriptomics.
CellCarta runs a wide range of commercial and clinically validated assays. Panels validated for clinical use include the oncoReveal CDx Pan-Cancer Solid Tumor IVD/FDA assay (Pillar Biosciences), TruSight Oncology Comprehensive (TSO Comp, Illumina), and HLA typing. We also support a broader portfolio of off-the-shelf panels, including TSO500, TruSeq RNA Exome, 10x Genomics Chromium, and Twist Comprehensive Exome, as well as custom panel development for mutation detection and gene expression.
View our full genomic assay list here.
CellCarta's data science team can perform detailed analysis of your NGS outputs. Where standard analysis fall short, we build custom computational pipelines for advanced applications, including RNA analysis and immune profiling workflows. NGS insights can also be integrated with data from our other service areas, including IHC, proteomics, and FISH.
Illumina-based workflows are analyzed using Illumina Connected Analytics (ICA), a secure, cloud-based bioinformatics platform that supports pipeline customization at any scale.
Yes. CellCarta offers fully scalable NGS solutions — from small, targeted panels to large biomarker programs — supporting studies at every stage of development. With cross-validated instrumentation and processes in facilities across the globe, we provide seamless global study support to ensure consistency across all sites.
